Moody Aldrich Partners LLC Sells 651 Shares of Balchem Co. (NASDAQ:BCPC)

Moody Aldrich Partners LLC cut its position in shares of Balchem Co. (NASDAQ:BCPC) by 2.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 29,662 shares of the basic materials company’s stock after selling 651 shares during the period. Moody Aldrich Partners LLC’s holdings in Balchem were worth $5,221,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Congress Wealth Management LLC DE raised its holdings in shares of Balchem by 6.2% in the first quarter. Congress Wealth Management LLC DE now owns 43,287 shares of the basic materials company’s stock worth $6,708,000 after buying an additional 2,510 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Balchem by 1.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 83,221 shares of the basic materials company’s stock worth $12,895,000 after purchasing an additional 1,553 shares in the last quarter. Norden Group LLC purchased a new position in Balchem in the 1st quarter worth $430,000. Commonwealth Equity Services LLC raised its stake in Balchem by 4.9% in the 1st quarter. Commonwealth Equity Services LLC now owns 14,722 shares of the basic materials company’s stock worth $2,281,000 after acquiring an additional 691 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Balchem by 21.8% in the 1st quarter. BNP Paribas Financial Markets now owns 37,117 shares of the basic materials company’s stock worth $5,751,000 after acquiring an additional 6,652 shares during the last quarter. 87.91% of the stock is owned by institutional investors.

Balchem Trading Down 0.5 %

BCPC traded down $0.89 on Thursday, hitting $165.87. The company had a trading volume of 5,841 shares, compared to its average volume of 105,298. The firm has a market cap of $5.38 billion, a P/E ratio of 47.11, a PEG ratio of 5.43 and a beta of 0.65. Balchem Co. has a 1 year low of $110.74 and a 1 year high of $186.03. The company’s fifty day moving average price is $171.60 and its 200 day moving average price is $162.09. The company has a current ratio of 2.83, a quick ratio of 1.79 and a debt-to-equity ratio of 0.26.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings data on Friday, July 26th. The basic materials company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The business had revenue of $234.08 million during the quarter, compared to the consensus estimate of $241.26 million. Balchem had a return on equity of 10.94% and a net margin of 12.52%. As a group, equities analysts expect that Balchem Co. will post 3.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on BCPC shares. StockNews.com lowered Balchem from a “buy” rating to a “hold” rating in a research note on Monday, July 29th. HC Wainwright lifted their price target on shares of Balchem from $170.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st.

Insider Buying and Selling at Balchem

In other news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total transaction of $1,395,387.50. Following the completion of the sale, the senior vice president now owns 8,540 shares in the company, valued at $1,537,627. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.25% of the stock is owned by company insiders.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.